

# Resource Summary Report

Generated by [NIF](#) on Sep 5, 2026

## A-431

RRID:CVCL\_0037

Type: Cell Line

---

### Proper Citation

RRID:CVCL\_0037

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_0037](https://web.expasy.org/cellosaurus/CVCL_0037)

**Proper Citation:** RRID:CVCL\_0037

**Description:** Cell line A-431 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Skin squamous cell carcinoma

**Defining Citation:** [PMID:212188](#), [PMID:1394225](#), [PMID:2228902](#), [PMID:2758419](#), [PMID:2990217](#), [PMID:4357758](#), [PMID:6092175](#), [PMID:6173755](#), [PMID:6254071](#), [PMID:6500159](#), [PMID:6954533](#), [PMID:6983291](#), [PMID:9290701](#), [PMID:9887230](#), [PMID:11416159](#), [PMID:11668190](#), [PMID:16957166](#), [PMID:17124637](#), [PMID:17178626](#), [PMID:18568074](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22108792](#), [PMID:22282976](#), [PMID:23637631](#), [PMID:24804581](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25894527](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:26989177](#), [PMID:27397505](#), [PMID:28176443](#), [PMID:30894373](#), [PMID:35839778](#)

**Comments:** Karyotypic information: Hypertriploid karyotype (ATCC=CRL-1555)., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: Human Protein Atlas, Cell Atlas panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** A-431

**Synonyms:** A431, A431/P

**Cross References:** BTO:BTO\_0000017, CLO:CLO\_0001591, CLO:CLO\_0001592, CLO:CLO\_0050011, CLO:CLO\_0050012, EFO:EFO\_0006268, MCCL:MCC:0000025, CLDB:cl155, CLDB:cl156, CLDB:cl157, CLDB:cl159, CLDB:cl160, CLDB:cl161, Abcam:ab263975, Abcam:ab275462, AddexBio:C0012001/22, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, ATCC:CRL-1555, ATCC:CRL-7907, BCRC:60161, BCRJ:0032, BioGRID\_ORCS\_Cell\_line:1572, BioSample:SAMN01821614, BioSample:SAMN01821671, BioSample:SAMN01821724, BioSample:SAMN03472220, cancercellines:CVCL\_0037, CCRID:1101HUM-PUMC000092, CCRID:3101HUMSCSP5042, CCRID:3101HUMTCHu188, CCRID:4201HUM-CCTCC00084, CCTCC:GDC0084, Cell\_Model\_Passport:SIDM00995, ChEMBL-Cells:ChEMBL3307523, ChEMBL-Targets:ChEMBL614069, CLS:300112, Cosmic:688038, Cosmic:735609, Cosmic:755305, Cosmic:876559, Cosmic:897743, Cosmic:910564, Cosmic:910925, Cosmic:974317, Cosmic:1071898, Cosmic:1176624, Cosmic:1351516, Cosmic:1477434, Cosmic:1945879, Cosmic:1995334, Cosmic:2131571, Cosmic:2301592, Cosmic:2646654, Cosmic-CLP:910925, DepMap:ACH-001328, DSMZ:ACC-91, DSMZCellDive:ACC-91, ECACC:85090402, EGA:EGAS00001000610, EGA:EGAS00001000978, FANTOM5\_SSTAR:10426-106D3, GDSC:910925, GEO:GSM183432, GEO:GSM183433, GEO:GSM270524, GEO:GSM270525, GEO:GSM270526, GEO:GSM827302, GEO:GSM1374384, GEO:GSM1669586, GEO:GSM2112551, GEO:GSM2112555, GEO:GSM7701410, GEO:GSM7701411, IARC\_TP53:21167, IARC\_TP53:23618, IZSLER:BS TCL 161, JCRB:IFO50411, JCRB:JCRB0004, JCRB:JCRB9009, KCB:KCB 200651YJ, KCLB:21555, KCLB:80005, LINCS\_LDP:LCL-1404, Lonza:814, NCBI\_Iran:C204, PharmacDB:A431\_46\_2019, PRIDE:PXD000065, PRIDE:PXD000589, PRIDE:PXD000681, PRIDE:PXD001582, PRIDE:PXD003937, PRIDE:PXD005301, PRIDE:PXD006291, PRIDE:PXD007206, PRIDE:PXD008996, PRIDE:PXD017536, PRIDE:PXD030304, PRIDE:PXD030984, PRIDE:PXD033685, Progenetix:CVCL\_0037, PubChem\_Cell\_line:CVCL\_0037, RCB:RCB0202, RCB:RCB1872, TKG:TKG 0182, TOKU-E:476, Ubigen:YC-D016, Wikidata:Q4649310

**ID:** CVCL\_0037

**Record Creation Time:** 20220427T215104+0000

**Record Last Update:** 20260904T021131+0000

---

## Ratings and Alerts

No rating or validation information has been found for A-431.

**Warning:** Discontinued: ATCC; CRL-7907

Karyotypic information: Hypertriploid karyotype (ATCC=CRL-1555)., Population: Caucasian., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: Human Protein Atlas, Cell Atlas panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

---

## Data and Source Information

**Source:** [Cellosaurus](#)

## Usage and Citation Metrics

We found 1226 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. *Cancer discovery*, 16(1), 81.

Lukowicz C, et al. (2026) An estrogen receptor/E2F1/CDKN3 axis protects from UV-induced skin cancers in females. *EMBO reports*, 27(9), 2434.

Zhang Z, et al. (2026) A Moderate-Affinity Antibody-Drug Conjugate Targeting B7-H3 Exerts Potent Antitumor Efficacy. *Pharmaceuticals (Basel, Switzerland)*, 19(4).

Thamm E, et al. (2026) THC and CBD Induce Heme Oxygenase-1-Dependent Cell Death and Trigger Mitochondrial Dysfunction in Human Melanoma and Cutaneous Squamous Cell Carcinoma Cells. *Antioxidants (Basel, Switzerland)*, 15(3).

Stanland LJ, et al. (2026) Protocols to evaluate mutant specificity of an oncogene-targeting siRNA using orthogonal in vitro and in vivo approaches. *STAR protocols*, 7(1), 104323.

Petrilli A, et al. (2026) Solute carrier family (SLC) amino acid transporters are upregulated in cutaneous squamous cell carcinoma. *Biology direct*, 21(1), 17.

Oroujeni M, et al. (2026) Preclinical evaluation of an antibody-based companion diagnostic for CD44v6 expressing cancer. *Nuclear medicine communications*, 47(4), 401.

Park K, et al. (2026) KLS-3021: Innovative oncolytic virotherapy for the treatment of advanced primary and metastatic cutaneous squamous cell carcinoma. *Molecular therapy. Oncology*, 34(2), 201182.

Le T, et al. (2026) Cell shapes decode molecular phenotypes in image-based spatial proteomics. *Cell systems*, 17(6), 101589.

Yang B, et al. (2026) Identification of PI3K/AKT/mTOR-related genes as diagnostic biomarkers for cutaneous squamous cell carcinoma. *Biochemistry and biophysics reports*, 45, 102355.

Larsson E, et al. (2026) Lipid packing contributes to the confinement of caveolae to the plasma membrane. *eLife*, 14.

Szkalitsity ??, et al. (2025) Nuclear??envelope-associated lipid droplets are enriched in cholesteryl esters and increase during inflammatory signaling. *The EMBO journal*, 44(10), 2774.

Moore GL, et al. (2025) A B7-H3-Targeted CD28 Bispecific Antibody Enhances the Activity of Anti-PD-1 and CD3 T-cell Engager Immunotherapies. *Molecular cancer therapeutics*, 24(3), 331.

Wang X, et al. (2025) Machine-learning-assisted universal protein activation in living mice. *Cell*, 188(14), 3696.

Qiu T, et al. (2025) Dynamic PRDX S-acylation modulates ROS stress and signaling. *Cell chemical biology*, 32(3), 511.

Lang PA, et al. (2025) Optimized arenaviruses with tumor-tropic mutations promote safe anti-tumor efficacy via sustainable immune modulatory properties. *Cell reports. Medicine*, 6(10), 102411.

Normand L, et al. (2025) Tks5 interactome reveals endoplasmic-reticulum-associated translation machinery in invadosomes. *The FEBS journal*.

Hassan A, et al. (2025) IL-6-mediated tumorigenicity and antioxidant state in squamous cell carcinoma cells are driven by CD109 via stabilization of IL-6 receptor-alpha and activation of STAT3/NRF2 pathway. *Experimental hematology & oncology*, 14(1), 64.

Ramchatesingh B, et al. (2025) Targeting PRAME directly or via EZH2 inhibition overcomes retinoid resistance and represents a novel therapy for keratinocyte carcinoma. *Molecular oncology*, 19(5), 1471.

Thomas BJ, et al. (2025) DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma. *Cancer immunology research*, 13(11), 1798.